5H,6H,7H,8H-(1,2,4)triazolo(4,3-a)pyrazine → HCID 58117148, compound
Reaction equation
[Cl:1][C:2]1[N:3]=[C:4]([N:21]2[CH2:26][CH2:25][O:24][CH2:23][CH2:22]2)[C:5]2[S:10][C:9]([CH2:11][N:12]3[CH2:17][CH2:16][NH:15][C:14](=O)[C:13]3([CH3:20])C)=[CH:8][C:6]=2[N:7]=1.[N:27]1[N:28]=CN2CCNCC=12>>[Cl:1][C:2]1[N:3]=[C:4]([N:21]2[CH2:26][CH2:25][O:24][CH2:23][CH2:22]2)[C:5]2[S:10][C:9]([CH2:11][N:12]3[CH2:17][CH2:16][N:15]4[CH:14]=[N:27][N:28]=[C:20]4[CH2:13]3)=[CH:8][C:6]=2[N:7]=1Participants
3
Procedure
Prepared according to the method used in the preparation of 4-(2-chloro-4-morpholin-4-yl-thieno[3,2-d]pyrimidin-6-ylmethyl)-3,3-dimethyl-piperazin-2-one using 5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine in place of 3,3-dimethyl-piperazin-2-one. The title compound was obtained as a white solid (115 mg, 84%).
Workup
- customPrepared
Sources & evidence
- ORD record
- ord-2d684e1ea75142119c76855a25797c8a
- Source dataset
- uspto-grants-2012_10
- Patent number
- US08293735B2
Reaction notes
Loading…